Back to search

Article

Efficacy and toxicity of combined inhibition of EGFR and VEGF in patients with advanced non-small-cell lung cancer harboring activating EGFR mutations: A systematic review and meta-analysis

2022-05-11

Abstract excerpt

<h4>Purpose: </h4> Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways have demonstrated promising results for treatment of advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. We conducted a systematic review and meta-analysis to assess the efficacy and toxicity of combined treatment with EGFR tyrosine kinase inhibitors (TKIs) and VEGF...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7514a98f-8ed0-5dfa-973b-3f7a18eedd3d
DOI
10.21203/rs.3.rs-1523595/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and toxicity of combined inhibition of EGFR and VEGF in patients with advanced non-small-cell lung cancer harboring activating EGFR mutations: A systematic review and meta-analysisDOI 10.21203/rs.3.rs-1523595/v2
Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non-small Cell Lung Cancer Harboring Activating EGFR Mutations: A Systematic Review and Meta-analysis.Semantic proximity
Efficacy and safety of first-line treatments for patients with advanced epidermal growth factor receptor mutated non-small cell lung cancer: a network meta- analysisSemantic proximity
Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis.Semantic proximity
Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.Semantic proximity
EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.Semantic proximity
First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trialsSemantic proximity
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity
Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Semantic proximity
Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).Semantic proximity
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.Semantic proximity
Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.Semantic proximity
EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysisSemantic proximity
Select a neighboring publication to make it the new centre.